Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials


Madalina Dinca | Maria-Corina Serban | Amirhossein Sahebkar | Dimitri P. Mikhailidis | Peter P. Toth | Seth S. Martin | Michael J. Blaha | Matthias Blüher | Camelia Gurban | Peter Penson | Erin D. Michos | Adrian V. Hernandez | Steven R. Jones | Maciej Banach | for Lipid Blood Pressure Meta-analysis Collaboration LBPMC Group


We aimed to elucidate the role of vitamin D supplementation on adipokines through a systematic review and a meta-analysis of randomized placebo-controlled trials (RCTs). The search included PUBMED, Scopus, Web of Science and Google Scholar through July 1st, 2015. Finally we identified 9 RCTs and 484 participants. Meta-analysis of data from 7 studies did not find a significant change in plasma adiponectin concentrations following vitamin D supplementation (mean difference [MD]: 4.45%, 95%CI: ⿿3.04, 11.93, p = 0.244; Q = 2.18, I2 = 0%). In meta-regression, changes in plasma adiponectin concentrations following vitamin D supplementation were found to be independent of treatment duration (slope: 0.25; 95%CI: ⿿0.69, 1.19; p = 0.603) and changes in serum 25-hydroxy vitamin D [25(OH)D] levels (slope: ⿿0.02; 95%CI: ⿿0.15, 0.12; p = 0.780). Meta-analysis of data from 6 studies did not find a significant change in plasma leptin concentrations following vitamin D supplementation (MD: ⿿4.51%, 95%CI: ⿿25.13, 16.11, p = 0.668; Q = 6.41, I2 = 21.97%). Sensitivity analysis showed that this effect size is sensitive to one of the studies; removing it resulted in a significant reduction in plasma leptin levels (MD: ⿿12.81%, 95%CI: ⿿24.33, ⿿1.30, p = 0.029). In meta-regression, changes in plasma leptin concentrations following vitamin D supplementation were found to be independent of treatment duration (slope: ⿿1.93; 95%CI: ⿿4.08, 0.23; p = 0.080). However, changes in serum 25(OH)D were found to be significantly associated with changes in plasma leptin levels following vitamin D supplementation (slope: 1.05; 95%CI: 0.08, 2.02; p = 0.033). In conclusion, current data did not indicate a significant effect of vitamin D supplementation on adiponectin and leptin levels.


The authors declare no competing financial interests. This meta-analysis was written independently; no company or institution supported it financially. No professional writer was involved in the preparation of this meta-analysis. The meta-analysis has been prepared within Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group ( The authors declare no competing financial interests.

  1. Y. MatsuzawaAdiponectin: identification, physiology and clinical relevance in metabolic and vascular disease
    Atheroscler. Suppl.
  2. A.M. Belenchia et al.Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial
    Am. J. Clin. Nutr.
  3. A. Breslavsky et al.Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients
    Clin. Nutr.
  4. S. Shah et al.Large doses of vitamin D fail to increase 25-hydroxyvitamin D levels or to alter cardiovascular risk factors in obese adolescents: a pilot study
    J. Adolesc. Health
  5. S. Lee et al.Identification of a functional vitamin D response element in the murine Insig-2 promoter and its potential role in the differentiation of 3T3-L1 preadipocytes
    Mol. Endocrinol.
  6. T. Kulie et al.Vitamin D: an evidence-based review
    J. Am. Board Fam. Med.
  7. S.J. Mutt et al.Vitamin D and adipose tissue⿿more than storage
    Front. Physiol.
  8. M. Sahay et al.Rickets⿿vitamin D deficiency and dependency
    Indian J. Endocrinol. Metab.
  9. C. Ding et al.Vitamin D signalling in adipose tissue
    Br. J. Nutr.
  10. P. Norman et al.Vitamin D and cardiovascular disease
    Circ. Res.
  11. X. Palomer et al.Role of vitamin D in the pathogenesis of type 2 diabetes mellitus
    Diabetes Obesity Metab.
  12. M.B. Zemel et al.Calcitriol and energy metabolism
    Nutr. Rev.
  13. V.G. Athyros et al.Should adipokines be considered in the choice of the treatment of obesity-related health problems
    Curr. Drug Targets
  14. N. Rasouli et al.Adipocytokines and the metabolic complications of obesity
    J. Clin. Endocrinol. Metab.
  15. M.-H. Gannagé-Yared et al.Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young middle-eastern population
    Eur. J. Endocrinol.
  16. D.A. de Luis et al.Relation of leptin and adiponectin with cardiovascular risk factors, intact parathormone, and vitamin D levels in patients with primary hyperparathyroidism
    J. Clin. Lab. Anal.
  17. T. Di Chiara et al.Hypoadiponectinemia: a link between visceral obesity and metabolic syndrome
    J. Nutr. Metab.
  18. M. Trujillo et al.Adiponectin⿿journey from an adipocyte secretory protein to biomarker of the metabolic syndrome
    J. Intern. Med.
  19. K. Hotta et al.Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients
    Arterioscler. Thromb. Vasc. Biol.
  20. M.W. Schwartz et al.Central nervous system control of food intake
  21. X. Sun et al.Calcium and 1,25-dihydroxyvitamin D3 regulation of adipokine expression
  22. F. Kardas et al.Cardiometabolic risk factors related to vitamin d and adiponectin in obese children and adolescents
    Int. J. Endocrinol.
  23. D. Moher et al.Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
  24. Cochrane Handbook for Systematic Reviews of Interventions